{"id":742,"date":"2017-10-06T11:06:30","date_gmt":"2017-10-06T11:06:30","guid":{"rendered":"http:\/\/cryoviva.com.sg\/?page_id=742"},"modified":"2023-05-20T17:40:18","modified_gmt":"2023-05-20T09:40:18","slug":"literature-reference","status":"publish","type":"page","link":"https:\/\/ontarget-media.com\/cryoviva_new\/literature-reference\/","title":{"rendered":"Literature \/ Reference"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"742\" class=\"elementor elementor-742\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-dac0c1f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"dac0c1f\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2b23963\" data-id=\"2b23963\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7dc1d17 elementor-widget elementor-widget-text-editor\" data-id=\"7dc1d17\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.13.1 - 09-05-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p><strong><em>During pregnancy, if the mother suffers from organ damage, the baby in the womb sends stem cells to repair the damaged organ<br \/><\/em><\/strong>Dawe GS, Tan XW, Xiao Z-C. Cell Migration from Baby to Mother.\u00a0<em>Cell Adhesion &amp; Migration<\/em>. 2007;1(1):19-27.<br \/><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2633676\/\"><em>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2633676\/<\/em><\/a><em>\u00a0Accessed July 26, 2017<\/em><\/p><p><strong><em>The probability of finding a donor stem cell source through a public bank is low. Banking cord blood with a family bank increases the chances of having a matched unit available.<\/em><\/strong><\/p><p>Beatty PG, Boucher KM, Mori M, Milford EL. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol. 2000;61(8):834-840.<\/p><p><strong><em>Graft versus Host Disease (GVHD)<\/em><\/strong><strong><em>\u00a0is a common side effect of any transplant when the immune cells of the recipient\u2019s body do not recognize the donor\u2019s cells and start attacking them, thus leading to failure of the transplant.<\/em><\/strong><\/p><p>Lee, Stephanie J.; Vogelsang, Georgia; Flowers, Mary E.D. (2003). \u201cChronic graft-versus-host disease\u201d.\u00a0Biology of Blood and Marrow Transplantation.\u00a0<strong>9<\/strong>\u00a0(4): 215\u201333<\/p><p><strong><em>\u00a0<\/em><\/strong><\/p><p><strong><em>GVHD is broadly categorized into two types, the acute and chronic where its symptoms can range from modest to serious.<\/em><\/strong><\/p><p><a href=\"http:\/\/www.lls.org\/...\/f-73147405621_AvrIWIiW_bloodmarrowstemcelltransplantation.pdf\">www.lls.org\/\u2026\/f-73147405621_AvrIWIiW_bloodmarrowstemcelltransplantation.pdf<\/a>. Accessed September 7, 2017<\/p><p><strong><em>\u00a0<\/em><\/strong><\/p><p><strong><em>Cord blood is currently used in the treatment of around 80 diseases,<\/em><\/strong><br \/><a href=\"http:\/\/www.viacord.com\/treatments-and-research\/treatable-diseases-today\/index.aspx\">Data on file<\/a>. \u00a0Retrieved June 13, 2017 from ViaCord.com .PerkinElmer, Inc. \u00a0Most of the diseases on this list are inherited genetic diseases. \u00a0Typically, these treatments require a donor transplant, such as from a sibling. \u00a0If your child needs a donor, a family member is always the first-choice source. \u00a0Treatments for cancers like neuroblastoma can use a child\u2019s own cord blood. \u00a0Although the potential use of newborn stem cells is expanding rapidly, the odds a family member without a defined risk will need to use their child\u2019s stem cells are low. \u00a0Banking cord blood does not guarantee that treatment will be effective and only a treating physi7cian can determine when it can be used.<\/p><p>Umbilical Cord Blood: Information for Childbirth Educators; Renece Waller-Wise, The Journal of Perinatal Education, 20(1), 54\u201360; Cord Blood Registry | Parent\u2019s Guide to Cord Blood, July 19 2017; Cord Blood and the FDA \u2013 Parent\u2019s Guide to Cord Blood, March 11 , 2016<\/p><p><strong><em>Transplant outcomes are better with related cord blood donor cells compared with unrelated cord blood or bone marrow donor cells.<br \/><\/em><\/strong>Gluckman E, Rocha V, Boyer-Chammard A, et al. For the Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373-381.<\/p><p><strong><em>Hematopoietic cell transplantation (HCT) of umbilical cord origin can benefit for malignant and nonmalignant diseases like Fanconi\u2019s anemia, aplastic anemia, leukemias, bone marrow failure syndromes, inborn error of metabolism, congenital disorders and hemoglobinopathies<\/em><\/strong><\/p><ul><li>Pai S-Y, Logan B, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371: 434\u201346.<\/li><li>Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121: 3981\u20137.<\/li><li>Myers KC, Davies S. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15(3):279\u201392.<\/li><li>King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089\u20134.<\/li><\/ul><p><strong><u>Diseases\u00a0Treatable with Cord Blood Transplant<\/u><\/strong><br \/><strong>Blood Disorders<\/strong><\/p><ol><li><strong>Leukemia<br \/><\/strong>Damaris Christensen; Umbilical Cord Blood Offers Another Option for Leukemia Patients.\u00a0<em>Journal of the National Cancer Institute<\/em>, Volume 97, Issue 4, 16 February 2005, Pages 253\u2013254.<br \/>Laughlin M, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukaemia.\u00a0<em>New England Journal of Medicine<\/em>. 2004; 351:2265-2275.<\/li><li><strong>Lymphomas<br \/><\/strong>Yuji, K., Miyakoshi, S., Kato, D., Miura, Y., Myojo, T., &amp; Murashige, N. et al. (2005). Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.\u00a0Biology Of Blood And Marrow Transplantation,\u00a011(4), 314-318.<\/li><\/ol><p><strong>Blood cell proliferation disorders<br \/><\/strong><strong>1.Anaemias<br \/><\/strong>Hassall, O. W., Thitiri, J., Fegan, G., Hamid, F., Mwarumba, S., Denje, D., \u2026 Bates, I. (2015). Safety and efficacy of allogeneic umbilical cord red blood cell transfusion for children with severe anaemia in a Kenyan hospital: an open-label single-arm trial.\u00a0The Lancet. Haematology,\u00a02(3), e101\u2013e107.<br \/>Prasad, V., &amp; Kurtzberg, J. (2009). Umbilical cord blood transplantation for non-malignant diseases.\u00a0Bone Marrow Transplantation,\u00a044(10), 643-651.<br \/><strong><br \/><\/strong><strong>Inherited Immune System Disorders<\/strong><\/p><ol><li><strong>Severe Combined Immunodeficiency (<\/strong><strong>SCID with Adenosine Deaminase Deficiency (ADA-SCID), SCID which is X-linked, SCID with absence of T &amp; B Cells, SCID with absence of T Cells, Normal B Cells, Omenn Syndrome, Neutropenias, Infantile Genetic Agranulocytosis (Kostmann Syndrome), Myelokathexis)<br \/><\/strong>Dvorak, C., &amp; Cowan, M. (2007). Hematopoietic stem cell transplantation for primary immunodeficiency disease.\u00a0Bone Marrow Transplantation,\u00a041(2), 119-126.<br \/>Slatter, M., &amp; Cant, A. (2011). Hematopoietic stem cell transplantation for primary immunodeficiency diseases.\u00a0Annals Of The New York Academy Of Sciences,\u00a01238(1), 122-131.<\/li><li><strong>Ataxia-Telangiectasia, Bare Lymphocyte Syndrome, DiGeorge Syndrome, Hemophagocytic Lymphohistiocytosis, Leukocyte Adhesion Deficiency, Leukocyte Adhesion Deficiency, Lymphoproliferative Disorder, X-linked (Susceptibility to Epstein-Barr virus), Wiskott-Aldrich Syndrome, Myeloproliferative Disorders, Acute Myelofibrosis, Agnogenic Myeloid Metaplasia (Myelofibrosis), Polycythemia Vera, Essential Thrombocythemia<\/strong><br \/>Knutsen, A., Steffen, M., Wassmer, K. and Wall, D. (2003). Umbilical cord blood transplantation in Wiskott Aldrich syndrome.\u00a0The Journal of Pediatrics, 142(5), pp.519-523.<br \/>Robin, M., Giannotti, F., Deconinck, E., Mohty, M., Michallet, M., Sanz, G., . . . Ruggeri, A. (2014). Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis.\u00a0Biology of Blood and Marrow Transplantation,\u00a020(11), 1841-1846.<\/li><\/ol><p><strong>Phagocyte Disorders<\/strong><\/p><p><strong>Chediak-Higashi Syndrome, Chronic Granulomatous Disease, Neutrophil Actin Deficiency, Reticular Dysgenesis<\/strong><br \/>Bhattacharya, A., Slatter, M., Curtis, A., Chapman, C., Barge, D., Jackson, A., Flood, T., Abinun, M., Cant, A. and Gennery, A. (2003). Successful umbilical cord blood stem cell transplantation for chronic granulomatous disease.\u00a0Bone Marrow Transplantation, 31(5), pp.403-405.<br \/>Reubsaet, L., Boelens, J., Rademaker, C., Smal, J. and Wulffraat, N. (2007). Successful cord blood transplantation in a premature and dysmature neonate of 1700 g with reticular dysgenesis.\u00a0Bone Marrow Transplantation, 39(5), pp.307-308.<br \/>Zhang, Y., Gao, Z. and Yu, X. (2017). A case of Chediak-Higashi syndrome presented with accelerated phase could be treated effectively by unrelated cord blood transplantation.\u00a0Pediatric Transplantation, p.e13014<\/p><p><strong>Bone Marrow Cancers<br \/>Multiple Myeloma, Plasma Cell Leukemia, Waldenstrom\u2019s Macroglobulinemi<br \/><\/strong>Kawamura, K., Takamatsu, H., Ikeda, T., Komatsu, T., Aotsuka, N., Amano, I., Yamamoto, G., Watanabe, K., Ohno, Y., Matsue, K., Kouzai, Y., Tsukada, N., Ishiyama, K., Anzai, N., Kato, K., Suzuki, R., Sunami, K. and Kanda, Y. (2015). Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.\u00a0Biology of Blood and Marrow Transplantation, 21(7), pp.1291-1298.<\/p><p><strong>Inherited Disorders of the Immune System &amp; Other Organs<br \/><\/strong><strong>Cartilage-Hair Hypoplasia, Erythropoietic Porphyria, Hermansky-Pudlak Syndrome, Pearson\u2019s Syndrome, Shwachman-Diamond Syndrome, Systemic Mastocytosis<br \/><\/strong>Allewelt, H., Patel, S., Prasad, V., Kurtzberg, J., Driscoll, T., Martin, P., Page, K. and Parikh, S. (2016). Umbilical Cord Blood Transplantation for Cartilage Hair Hypoplasia: A Single Center Experience Demonstrates Excellent Outcomes Using Myeloablative Preparative Regimens.\u00a0Biology of Blood and Marrow Transplantation, 22(3), p.S235.<\/p><p><strong>Inherited Metabolic Disorders<\/strong><\/p><ol><li><strong>Hurler Syndrome (MPS-IH), Scheie Syndrome (MPS-IS), Hunter Syndrome (MPS-II), Sanfilippo Syndrome (MPS-III), Morquio Syndrome (MPS-IV), Maroteaux-Lamy Syndrome (MPS-VI), Sly Syndrome (MPS-VII) (beta-glucuronidase deficiency),<\/strong><strong>\u00a0Mucolipidosis II (I-cell Disease),\u00a0<\/strong><strong>Leukodystrophy Disorders, Adrenoleukodystrophy (ALD), Krabbe Disease (Globoid Cell Leukodystrophy), Metachromatic Leukodystrophy, Pelizaeus-Merzbacher Disease<br \/><\/strong>Mullen, C., Thompson, J., Richard, L. and Chan, K. (2000). Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia.\u00a0Bone Marrow Transplantation, 25(10), pp.1093-1097.<br \/>Ooi, J. (2006). The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome.\u00a0Leukemia &amp; Lymphoma, 47(4), pp.599-602.<br \/>Prasad, V. K., Mendizabal, A., Parikh, S. H., Szabolcs, P., Driscoll, T. A., Page, K., \u2026 Kurtzberg, J. (2008). Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes.\u00a0Blood,\u00a0112(7), 2979\u20132989.<br \/>Stockman, J. (2006). Cord-Blood Transplants From Unrelated Donors in Patients With Hurler\u2019s Syndrome.\u00a0Yearbook of Pediatrics, 2006, pp.436-437.<br \/>Wood, S., Allison, J., Escolar, M., Provenzale, J. and Kurtzberg, J. (2006). Neonatal umbilical cord blood transplantation favourably alters the neurodevelopmental outcome and survival of babies with infantile Krabbe disease.\u00a0Biology of Blood and Marrow Transplantation, 12(2), pp.153-154.<\/li><li><strong>Niemann-Pick Disease,<\/strong>\u00a0<strong>Sandhoff Disease, Wolman Disease<\/strong><br \/>Martin, P., Carter, S., Kernan, N., Sahdev, I., Wall, D., Pietryga, D., Wagner, J. and Kurtzberg, J. (2006). Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases.\u00a0Biology of Blood and Marrow Transplantation, 12(2), pp.184-194.<\/li><li><strong>Lesch-Nyhan Syndrome<br \/><\/strong>K\u00e1llay, K., Liptai, Z., Beny\u00f3, G., Kassa, C., Goda, V., Sink\u00f3, J., T\u00f3th, \u00c1. and Kriv\u00e1n, G. (2012). Successful unrelated umbilical cord blood transplantation in Lesch-Nyhan syndrome.\u00a0Metabolic Brain Disease, 27(2), pp.193-196.<\/li><li><strong>Osteoporosis\/Osteopetrosis<\/strong><br \/>Chiesa, R., Ruggeri, A., Paviglianiti, A., Zecca, M., G\u00f3nzalez-Vicent, M., Bordon, V., Stein, J., Lawson, S., Dupont, S., Lanino, E., Abecasis, M., Al-Seraihy, A., Kenzey, C., Bierings, M., Locatelli, F., Gluckman, E., Schulz, A., Gennery, A., Page, K., Kurtzberg, J. and Rocha, V. (2016). Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis.\u00a0Biology of Blood and Marrow Transplantation, 22(11), pp.1997-2002.`<\/li><\/ol><p><strong>Other References for Clinical Trials<\/strong><\/p><p>CBR Clinical Trials and Stem Cell Research\u201d.\u00a0cordblood.com. CBR Systems, Inc. Retrieved\u00a021 January\u00a02014.<\/p><p>Cord Blood Registry | Parent\u2019s Guide to Cord Blood, July 19 2017<\/p><p>Cord Blood and the FDA \u2013 Parent\u2019s Guide to Cord Blood, March 11, 2016<\/p><p>National Cord Blood Program, 2015<\/p><p>National Marrow Donor Program 3 August 2011<\/p><p>Clinical Trials 3 August 2011<\/p><p>MedicineNet, 2012. Definition of Clinical Trials, 1 February 2014<\/p><p>Clinical trial registry page. ClinicalTrials.gov. Accessed Dec 2015.<strong><br \/><\/strong><\/p><p><strong>Hepatitis that stays dormant in the blood and can become active at a later time. This precaution and sample testing is important to ensure that the cord blood collected is<br \/>medically safe and clear of all infectious diseases in case the future recipient is immune-compromised.<\/strong><\/p><p>http:\/\/ www.scbb.com.sg\/donate\/faq\/Pages\/Home.aspx#top . Accessed August 15, 2017<\/p><p><strong>\u201cThis is a necessary step to ensure that the cord blood collected later are free from any infectious disease and safe for transplant\u2026\u201d<\/strong><br \/>FAQ, Retrieved 14 June 2017, from\u00a0<a href=\"http:\/\/www.scbb.com.sg\/donate\/faq\/Pages\/Home.aspx\">http:\/\/www.scbb.com.sg\/donate\/faq\/Pages\/Home.aspx<\/a><\/p><p><strong>Blood Sample from mother<\/strong><\/p><p><a href=\"http:\/\/www.nationalcordbloodprogram.org\/work\/collections.html\">http:\/\/www.nationalcordbloodprogram.org\/work\/collections.html<\/a>\u00a0Accessed July 25, 2017<\/p><p><strong>Cord Blood Collection<\/strong><br \/><a href=\"http:\/\/www.scbb.com.sg\/\">http:\/\/www.scbb.com.sg<\/a>\u00a0Accessed August 10, 2017<\/p><p><strong>Mesenchymal cells (MSCs) are applied in medical experiments to help treat a variety of medical conditions, especially in degenerative diseases, including cerebral palsy, autism ALS and Diabetes.<\/strong><\/p><ol><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers).<\/li><li>Singh Lipi et. al. Stem Cell Overview and Research in Diabetes. Indian Journal of Stem Cell Therapy, 2015:1(1): 29-38<\/li><li>Beeravolu N, Brougham J, Khan I, McKee C, Perez-Cruet M, Chaudhry GR Human umbilical cord derivatives regenerate intervertebral disc. J Tissue Eng Regen Med. 2016 Sep 30.<\/li><li>Zhang C, Yin X, Zhang J, Ao Q, Gu Y, Liu Y. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: A case report. Exp Ther Med. 2017 May;13(5):1922-1926.<\/li><li>Cui D, Li H, Xu X, Ye L, Zhou X, Zheng L, Zhou Y. Mesenchymal Stem Cells for Cartilage Regeneration of TMJ Osteoarthritis. Stem Cells Int. 2017;2017: 5979741.<\/li><li>Wang X1, Hu H1, Hua R1, Yang J1, Zheng P1, Niu X1, Cheng H1, Dai G1, Liu X1, Zhang Z1, An Y2. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy. 2015;17(2):224-31.<\/li><li>Nitkin CR, Bonfield TL. Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements. Stem Cells Transl Med. 2017;6(2):539-565. 2015-0427.<\/li><li>Ng TK, Fortino VR, Pelaez D, Cheung HS Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells. 2014;26;6(2):111-9<\/li><li>Bonafede R, Mariotti R. ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Front Cell Neurosci. 2017 Mar 21;11:80.<\/li><li>Tanna T, Sachan V. Mesenchymal stem cells: potential in treatment of neurodegenerative diseases. Curr Stem Cell Res Ther. 2014;9(6):513-21.<\/li><\/ol><p><strong>MSCs can be applied together with stem cells derived from cord blood in situations where there is a relatively low amount of haematopoietic stem cells within the cord blood<\/strong><\/p><ol><li>Minoo Battiwalla, and Peiman Hematti. Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation. Cytotherapy. 2009; 11(5): 503\u2013515.<\/li><li>Ke Zhao and Qifa Liu. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol. 2016; 9: 46. 2016<\/li><\/ol><p><strong>MSCs can be utilized to care for the whole family (there is no strict requirement for an HLA match as in the case of cord blood<\/strong><\/p><ol><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers).<\/li><li>Qinjun Zhao, Hongying Ren, Zhong Chao Han. Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. Journal of Cellular Immunotherapy. Volume 2, Issue 1, March 2016, Pages 3-20.<\/li><li>The immunomodulatory capacity of mesenchymal stem cells. Antje Gebler, Olivia Zabel, Barbara Seliger. The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine. 2012; Volume 18, Issue 2, p128\u2013134.<\/li><\/ol><p><strong>The Wharton\u2019s Jelly of the human cord is unique among connective tissues as it contains only Mesenchymal Cells that make up the functional myofibroblasts of the tissue and their predecessors<\/strong><\/p><p>John E. Davies, John T. Walker, Armand keating. Concise Review: Wharton\u2019s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cell Translational Medicine 2017;6 1620-1630<\/p><p><strong>The multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells)<\/strong><\/p><ol><li>Troyer DL, Weiss ML. Wharton\u2019s jelly-derived cells are a primitive stroma cell population. Stem Cells. 2008 ;26(3):591-9.<\/li><li>John E. Davies, John T. Walker, Armand keating. Concise Review: Wharton\u2019s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cell Translational Medicine 2017;6 1620-1630<\/li><\/ol><p><strong>The MSCs in Wharton\u2019s Jelly\u00a0<\/strong>are<strong>\u00a0the most primitive source with very high regenerative potential<\/strong><\/p><p>Troyer DL, Weiss ML. Wharton\u2019s jelly-derived cells are a primitive stroma cell population. Stem Cells. 2008 ;26(3):591-9.<\/p><p><strong>Mesenchymal Stem Cells are one of the most promising aspects of research and is increasingly being employed in regenerative medicine to treat Spinal cord injury, Cartilage injury, Brain injury, Wound healing, Rheumatoid Arthritis, Multiple sclerosis, Myocardial infraction, Alzheimer, Diabetes, etc<\/strong><\/p><ol><li>Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013 ;34(6):747-54.<\/li><li>https:\/\/clinicaltrials.gov\/<\/li><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers)<\/li><li>Singh Lipi et. al. Stem Cell Overview and Research in Diabetes. Indian Journal of Stem Cell Therapy, 2015:1(1): 29-38<\/li><\/ol><p><strong>Besides MSCs are considered as an immune privileged cell in consequence is being utilized in allogeneic organ transplantation, graft versus host diseases (GVHD) and efficient homing for the hematopoietic stem cell transplantation engraftment<\/strong><\/p><ol><li>Imran Ullah, Raghavendra Baregundi Subbarao, and Gyu Jin Rho. Human mesenchymal stem cells \u2013 current trends and future prospective. Biosci Rep. 2015; 35(2).<\/li><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers)<\/li><\/ol><p><strong>Our services include facilitation in the umbilical cord tissue collection, testing, processing and long-term storage of umbilical cord tissue, and its retrieval for any authorized treatment in future, or for participation in clinical trial for research use<\/strong><\/p><p>Imran Ullah, Raghavendra Baregundi Subbarao, and Gyu Jin Rho. Human mesenchymal stem cells \u2013 current trends and future prospective. Biosci Rep. 2015; 35(2).<\/p><p><strong>Disclaimer<\/strong><\/p><ul><li>The umbilical cord tissue banking program is not licensed\/certified by Ministry of Health (MOH) Singapore.<\/li><li>The clinical applications of umbilical cord tissue derived stem cells is under research, and under different phases of clinical trials in Singapore. However, it has not been granted in Singapore as a Standard Clinical Practice.<\/li><li>The clients interested in storing the Umbilical cord tissue of their baby as a precious resource of prenatal tissue, are subject to the clear understanding that stored tissue may never be used for any clinical application until there is enough evidence and approved by local authorities and regulatory guidelines during the time of usage for clinical or research purpose.<\/li><li>Umbilical cord stem cell therapies have enormous promise, but the science in each use is nevertheless in the developmental phase. Professional assessment and expertise is required in using cord tissue derived stem cells for any therapeutic purpose, and we urge anyone embarking on the role of stem cell therapies to confer the National Health Databases to assess current data from clinical trials and the FDA websites on human umbilical cord tissue should also be consulted to obtain its current valuation of any therapy.<\/li><li>This service does not endorse or insure any possible future use or disease cure<\/li><\/ul><p><strong>Breast milk contains the perfect mix of vitamins, protein and fat that are vital to the growth of your infants.<\/strong><\/p><p>https:\/\/www.webmd.com\/parenting\/baby\/nursing-basics#1 Accessed March 13, 2018<\/p><p><strong>It also provides antibodies that help your baby fight off viruses and bacteria, and is known to decrease the risk of them contracting to infections<\/strong><\/p><p>https:\/\/kellymom.com\/pregnancy\/bf-prep\/how_breastmilk_protects_newborns\/\u00a0Accessed March 13, 2018<\/p><p><strong>Mentally, mothers often feel more empowered to see their babies grow and thrive on their breast milk alone<\/strong><\/p><p>https:\/\/www.fitpregnancy.com\/baby\/breastfeeding\/20-breastfeeding-benefits-mom-baby\u00a0Accessed March 13, 2018<\/p><p><strong><em>During pregnancy, if the mother suffers from organ damage, the baby in the womb sends stem cells to repair the damaged organ<br \/><\/em><\/strong>Dawe GS, Tan XW, Xiao Z-C. Cell Migration from Baby to Mother.\u00a0<em>Cell Adhesion &amp; Migration<\/em>. 2007;1(1):19-27.<br \/><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2633676\/\"><em>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2633676\/<\/em><\/a><em>\u00a0Accessed July 26, 2017<\/em><\/p><p><strong><em>The probability of finding a donor stem cell source through a public bank is low. Banking cord blood with a family bank increases the chances of having a matched unit available.<\/em><\/strong><\/p><p>Beatty PG, Boucher KM, Mori M, Milford EL. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol. 2000;61(8):834-840.<\/p><p><strong><em>Graft versus Host Disease (GVHD)<\/em><\/strong><strong><em>\u00a0is a common side effect of any transplant when the immune cells of the recipient\u2019s body do not recognize the donor\u2019s cells and start attacking them, thus leading to failure of the transplant.<\/em><\/strong><\/p><p>Lee, Stephanie J.; Vogelsang, Georgia; Flowers, Mary E.D. (2003). \u201cChronic graft-versus-host disease\u201d.\u00a0Biology of Blood and Marrow Transplantation.\u00a0<strong>9<\/strong>\u00a0(4): 215\u201333<\/p><p><strong><em>\u00a0<\/em><\/strong><\/p><p><strong><em>GVHD is broadly categorized into two types, the acute and chronic where its symptoms can range from modest to serious.<\/em><\/strong><\/p><p><a href=\"http:\/\/www.lls.org\/...\/f-73147405621_AvrIWIiW_bloodmarrowstemcelltransplantation.pdf\">www.lls.org\/\u2026\/f-73147405621_AvrIWIiW_bloodmarrowstemcelltransplantation.pdf<\/a>. Accessed September 7, 2017<\/p><p><strong><em>\u00a0<\/em><\/strong><\/p><p><strong><em>Cord blood is currently used in the treatment of around 80 diseases,<\/em><\/strong><br \/><a href=\"http:\/\/www.viacord.com\/treatments-and-research\/treatable-diseases-today\/index.aspx\">Data on file<\/a>. \u00a0Retrieved June 13, 2017 from ViaCord.com .PerkinElmer, Inc. \u00a0Most of the diseases on this list are inherited genetic diseases. \u00a0Typically, these treatments require a donor transplant, such as from a sibling. \u00a0If your child needs a donor, a family member is always the first-choice source. \u00a0Treatments for cancers like neuroblastoma can use a child\u2019s own cord blood. \u00a0Although the potential use of newborn stem cells is expanding rapidly, the odds a family member without a defined risk will need to use their child\u2019s stem cells are low. \u00a0Banking cord blood does not guarantee that treatment will be effective and only a treating physi7cian can determine when it can be used.<\/p><p>Umbilical Cord Blood: Information for Childbirth Educators; Renece Waller-Wise, The Journal of Perinatal Education, 20(1), 54\u201360; Cord Blood Registry | Parent\u2019s Guide to Cord Blood, July 19 2017; Cord Blood and the FDA \u2013 Parent\u2019s Guide to Cord Blood, March 11 , 2016<\/p><p><strong><em>Transplant outcomes are better with related cord blood donor cells compared with unrelated cord blood or bone marrow donor cells.<br \/><\/em><\/strong>Gluckman E, Rocha V, Boyer-Chammard A, et al. For the Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373-381.<\/p><p><strong><em>Hematopoietic cell transplantation (HCT) of umbilical cord origin can benefit for malignant and nonmalignant diseases like Fanconi\u2019s anemia, aplastic anemia, leukemias, bone marrow failure syndromes, inborn error of metabolism, congenital disorders and hemoglobinopathies<\/em><\/strong><\/p><ul><li>Pai S-Y, Logan B, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371: 434\u201346.<\/li><li>Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121: 3981\u20137.<\/li><li>Myers KC, Davies S. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15(3):279\u201392.<\/li><li>King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089\u20134.<\/li><\/ul><p><strong><u>Diseases\u00a0Treatable with Cord Blood Transplant<\/u><\/strong><br \/><strong>Blood Disorders<\/strong><\/p><ol><li><strong>Leukemia<br \/><\/strong>Damaris Christensen; Umbilical Cord Blood Offers Another Option for Leukemia Patients.\u00a0<em>Journal of the National Cancer Institute<\/em>, Volume 97, Issue 4, 16 February 2005, Pages 253\u2013254.<br \/>Laughlin M, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukaemia.\u00a0<em>New England Journal of Medicine<\/em>. 2004; 351:2265-2275.<\/li><li><strong>Lymphomas<br \/><\/strong>Yuji, K., Miyakoshi, S., Kato, D., Miura, Y., Myojo, T., &amp; Murashige, N. et al. (2005). Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.\u00a0Biology Of Blood And Marrow Transplantation,\u00a011(4), 314-318.<\/li><\/ol><p><strong>Blood cell proliferation disorders<br \/><\/strong><strong>1.Anaemias<br \/><\/strong>Hassall, O. W., Thitiri, J., Fegan, G., Hamid, F., Mwarumba, S., Denje, D., \u2026 Bates, I. (2015). Safety and efficacy of allogeneic umbilical cord red blood cell transfusion for children with severe anaemia in a Kenyan hospital: an open-label single-arm trial.\u00a0The Lancet. Haematology,\u00a02(3), e101\u2013e107.<br \/>Prasad, V., &amp; Kurtzberg, J. (2009). Umbilical cord blood transplantation for non-malignant diseases.\u00a0Bone Marrow Transplantation,\u00a044(10), 643-651.<br \/><strong><br \/><\/strong><strong>Inherited Immune System Disorders<\/strong><\/p><ol><li><strong>Severe Combined Immunodeficiency (<\/strong><strong>SCID with Adenosine Deaminase Deficiency (ADA-SCID), SCID which is X-linked, SCID with absence of T &amp; B Cells, SCID with absence of T Cells, Normal B Cells, Omenn Syndrome, Neutropenias, Infantile Genetic Agranulocytosis (Kostmann Syndrome), Myelokathexis)<br \/><\/strong>Dvorak, C., &amp; Cowan, M. (2007). Hematopoietic stem cell transplantation for primary immunodeficiency disease.\u00a0Bone Marrow Transplantation,\u00a041(2), 119-126.<br \/>Slatter, M., &amp; Cant, A. (2011). Hematopoietic stem cell transplantation for primary immunodeficiency diseases.\u00a0Annals Of The New York Academy Of Sciences,\u00a01238(1), 122-131.<\/li><li><strong>Ataxia-Telangiectasia, Bare Lymphocyte Syndrome, DiGeorge Syndrome, Hemophagocytic Lymphohistiocytosis, Leukocyte Adhesion Deficiency, Leukocyte Adhesion Deficiency, Lymphoproliferative Disorder, X-linked (Susceptibility to Epstein-Barr virus), Wiskott-Aldrich Syndrome, Myeloproliferative Disorders, Acute Myelofibrosis, Agnogenic Myeloid Metaplasia (Myelofibrosis), Polycythemia Vera, Essential Thrombocythemia<\/strong><br \/>Knutsen, A., Steffen, M., Wassmer, K. and Wall, D. (2003). Umbilical cord blood transplantation in Wiskott Aldrich syndrome.\u00a0The Journal of Pediatrics, 142(5), pp.519-523.<br \/>Robin, M., Giannotti, F., Deconinck, E., Mohty, M., Michallet, M., Sanz, G., . . . Ruggeri, A. (2014). Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis.\u00a0Biology of Blood and Marrow Transplantation,\u00a020(11), 1841-1846.<\/li><\/ol><p><strong>Phagocyte Disorders<\/strong><\/p><p><strong>Chediak-Higashi Syndrome, Chronic Granulomatous Disease, Neutrophil Actin Deficiency, Reticular Dysgenesis<\/strong><br \/>Bhattacharya, A., Slatter, M., Curtis, A., Chapman, C., Barge, D., Jackson, A., Flood, T., Abinun, M., Cant, A. and Gennery, A. (2003). Successful umbilical cord blood stem cell transplantation for chronic granulomatous disease.\u00a0Bone Marrow Transplantation, 31(5), pp.403-405.<br \/>Reubsaet, L., Boelens, J., Rademaker, C., Smal, J. and Wulffraat, N. (2007). Successful cord blood transplantation in a premature and dysmature neonate of 1700 g with reticular dysgenesis.\u00a0Bone Marrow Transplantation, 39(5), pp.307-308.<br \/>Zhang, Y., Gao, Z. and Yu, X. (2017). A case of Chediak-Higashi syndrome presented with accelerated phase could be treated effectively by unrelated cord blood transplantation.\u00a0Pediatric Transplantation, p.e13014<\/p><p><strong>Bone Marrow Cancers<br \/>Multiple Myeloma, Plasma Cell Leukemia, Waldenstrom\u2019s Macroglobulinemi<br \/><\/strong>Kawamura, K., Takamatsu, H., Ikeda, T., Komatsu, T., Aotsuka, N., Amano, I., Yamamoto, G., Watanabe, K., Ohno, Y., Matsue, K., Kouzai, Y., Tsukada, N., Ishiyama, K., Anzai, N., Kato, K., Suzuki, R., Sunami, K. and Kanda, Y. (2015). Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.\u00a0Biology of Blood and Marrow Transplantation, 21(7), pp.1291-1298.<\/p><p><strong>Inherited Disorders of the Immune System &amp; Other Organs<br \/><\/strong><strong>Cartilage-Hair Hypoplasia, Erythropoietic Porphyria, Hermansky-Pudlak Syndrome, Pearson\u2019s Syndrome, Shwachman-Diamond Syndrome, Systemic Mastocytosis<br \/><\/strong>Allewelt, H., Patel, S., Prasad, V., Kurtzberg, J., Driscoll, T., Martin, P., Page, K. and Parikh, S. (2016). Umbilical Cord Blood Transplantation for Cartilage Hair Hypoplasia: A Single Center Experience Demonstrates Excellent Outcomes Using Myeloablative Preparative Regimens.\u00a0Biology of Blood and Marrow Transplantation, 22(3), p.S235.<\/p><p><strong>Inherited Metabolic Disorders<\/strong><\/p><ol><li><strong>Hurler Syndrome (MPS-IH), Scheie Syndrome (MPS-IS), Hunter Syndrome (MPS-II), Sanfilippo Syndrome (MPS-III), Morquio Syndrome (MPS-IV), Maroteaux-Lamy Syndrome (MPS-VI), Sly Syndrome (MPS-VII) (beta-glucuronidase deficiency),<\/strong><strong>\u00a0Mucolipidosis II (I-cell Disease),\u00a0<\/strong><strong>Leukodystrophy Disorders, Adrenoleukodystrophy (ALD), Krabbe Disease (Globoid Cell Leukodystrophy), Metachromatic Leukodystrophy, Pelizaeus-Merzbacher Disease<br \/><\/strong>Mullen, C., Thompson, J., Richard, L. and Chan, K. (2000). Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia.\u00a0Bone Marrow Transplantation, 25(10), pp.1093-1097.<br \/>Ooi, J. (2006). The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome.\u00a0Leukemia &amp; Lymphoma, 47(4), pp.599-602.<br \/>Prasad, V. K., Mendizabal, A., Parikh, S. H., Szabolcs, P., Driscoll, T. A., Page, K., \u2026 Kurtzberg, J. (2008). Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes.\u00a0Blood,\u00a0112(7), 2979\u20132989.<br \/>Stockman, J. (2006). Cord-Blood Transplants From Unrelated Donors in Patients With Hurler\u2019s Syndrome.\u00a0Yearbook of Pediatrics, 2006, pp.436-437.<br \/>Wood, S., Allison, J., Escolar, M., Provenzale, J. and Kurtzberg, J. (2006). Neonatal umbilical cord blood transplantation favourably alters the neurodevelopmental outcome and survival of babies with infantile Krabbe disease.\u00a0Biology of Blood and Marrow Transplantation, 12(2), pp.153-154.<\/li><li><strong>Niemann-Pick Disease,<\/strong>\u00a0<strong>Sandhoff Disease, Wolman Disease<\/strong><br \/>Martin, P., Carter, S., Kernan, N., Sahdev, I., Wall, D., Pietryga, D., Wagner, J. and Kurtzberg, J. (2006). Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases.\u00a0Biology of Blood and Marrow Transplantation, 12(2), pp.184-194.<\/li><li><strong>Lesch-Nyhan Syndrome<br \/><\/strong>K\u00e1llay, K., Liptai, Z., Beny\u00f3, G., Kassa, C., Goda, V., Sink\u00f3, J., T\u00f3th, \u00c1. and Kriv\u00e1n, G. (2012). Successful unrelated umbilical cord blood transplantation in Lesch-Nyhan syndrome.\u00a0Metabolic Brain Disease, 27(2), pp.193-196.<\/li><li><strong>Osteoporosis\/Osteopetrosis<\/strong><br \/>Chiesa, R., Ruggeri, A., Paviglianiti, A., Zecca, M., G\u00f3nzalez-Vicent, M., Bordon, V., Stein, J., Lawson, S., Dupont, S., Lanino, E., Abecasis, M., Al-Seraihy, A., Kenzey, C., Bierings, M., Locatelli, F., Gluckman, E., Schulz, A., Gennery, A., Page, K., Kurtzberg, J. and Rocha, V. (2016). Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis.\u00a0Biology of Blood and Marrow Transplantation, 22(11), pp.1997-2002.`<\/li><\/ol><p><strong>Other References for Clinical Trials<\/strong><\/p><p>CBR Clinical Trials and Stem Cell Research\u201d.\u00a0cordblood.com. CBR Systems, Inc. Retrieved\u00a021 January\u00a02014.<\/p><p>Cord Blood Registry | Parent\u2019s Guide to Cord Blood, July 19 2017<\/p><p>Cord Blood and the FDA \u2013 Parent\u2019s Guide to Cord Blood, March 11, 2016<\/p><p>National Cord Blood Program, 2015<\/p><p>National Marrow Donor Program 3 August 2011<\/p><p>Clinical Trials 3 August 2011<\/p><p>MedicineNet, 2012. Definition of Clinical Trials, 1 February 2014<\/p><p>Clinical trial registry page. ClinicalTrials.gov. Accessed Dec 2015.<strong><br \/><\/strong><\/p><p><strong>Hepatitis that stays dormant in the blood and can become active at a later time. This precaution and sample testing is important to ensure that the cord blood collected is<br \/>medically safe and clear of all infectious diseases in case the future recipient is immune-compromised.<\/strong><\/p><p>http:\/\/ www.scbb.com.sg\/donate\/faq\/Pages\/Home.aspx#top . Accessed August 15, 2017<\/p><p><strong>\u201cThis is a necessary step to ensure that the cord blood collected later are free from any infectious disease and safe for transplant\u2026\u201d<\/strong><br \/>FAQ, Retrieved 14 June 2017, from\u00a0<a href=\"http:\/\/www.scbb.com.sg\/donate\/faq\/Pages\/Home.aspx\">http:\/\/www.scbb.com.sg\/donate\/faq\/Pages\/Home.aspx<\/a><\/p><p><strong>Blood Sample from mother<\/strong><\/p><p><a href=\"http:\/\/www.nationalcordbloodprogram.org\/work\/collections.html\">http:\/\/www.nationalcordbloodprogram.org\/work\/collections.html<\/a>\u00a0Accessed July 25, 2017<\/p><p><strong>Cord Blood Collection<\/strong><br \/><a href=\"http:\/\/www.scbb.com.sg\/\">http:\/\/www.scbb.com.sg<\/a>\u00a0Accessed August 10, 2017<\/p><p><strong>Mesenchymal cells (MSCs) are applied in medical experiments to help treat a variety of medical conditions, especially in degenerative diseases, including cerebral palsy, autism ALS and Diabetes.<\/strong><\/p><ol><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers).<\/li><li>Singh Lipi et. al. Stem Cell Overview and Research in Diabetes. Indian Journal of Stem Cell Therapy, 2015:1(1): 29-38<\/li><li>Beeravolu N, Brougham J, Khan I, McKee C, Perez-Cruet M, Chaudhry GR Human umbilical cord derivatives regenerate intervertebral disc. J Tissue Eng Regen Med. 2016 Sep 30.<\/li><li>Zhang C, Yin X, Zhang J, Ao Q, Gu Y, Liu Y. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: A case report. Exp Ther Med. 2017 May;13(5):1922-1926.<\/li><li>Cui D, Li H, Xu X, Ye L, Zhou X, Zheng L, Zhou Y. Mesenchymal Stem Cells for Cartilage Regeneration of TMJ Osteoarthritis. Stem Cells Int. 2017;2017: 5979741.<\/li><li>Wang X1, Hu H1, Hua R1, Yang J1, Zheng P1, Niu X1, Cheng H1, Dai G1, Liu X1, Zhang Z1, An Y2. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy. 2015;17(2):224-31.<\/li><li>Nitkin CR, Bonfield TL. Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements. Stem Cells Transl Med. 2017;6(2):539-565. 2015-0427.<\/li><li>Ng TK, Fortino VR, Pelaez D, Cheung HS Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells. 2014;26;6(2):111-9<\/li><li>Bonafede R, Mariotti R. ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Front Cell Neurosci. 2017 Mar 21;11:80.<\/li><li>Tanna T, Sachan V. Mesenchymal stem cells: potential in treatment of neurodegenerative diseases. Curr Stem Cell Res Ther. 2014;9(6):513-21.<\/li><\/ol><p><strong>MSCs can be applied together with stem cells derived from cord blood in situations where there is a relatively low amount of haematopoietic stem cells within the cord blood<\/strong><\/p><ol><li>Minoo Battiwalla, and Peiman Hematti. Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation. Cytotherapy. 2009; 11(5): 503\u2013515.<\/li><li>Ke Zhao and Qifa Liu. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol. 2016; 9: 46. 2016<\/li><\/ol><p><strong>MSCs can be utilized to care for the whole family (there is no strict requirement for an HLA match as in the case of cord blood<\/strong><\/p><ol><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers).<\/li><li>Qinjun Zhao, Hongying Ren, Zhong Chao Han. Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. Journal of Cellular Immunotherapy. Volume 2, Issue 1, March 2016, Pages 3-20.<\/li><li>The immunomodulatory capacity of mesenchymal stem cells. Antje Gebler, Olivia Zabel, Barbara Seliger. The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine. 2012; Volume 18, Issue 2, p128\u2013134.<\/li><\/ol><p><strong>The Wharton\u2019s Jelly of the human cord is unique among connective tissues as it contains only Mesenchymal Cells that make up the functional myofibroblasts of the tissue and their predecessors<\/strong><\/p><p>John E. Davies, John T. Walker, Armand keating. Concise Review: Wharton\u2019s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cell Translational Medicine 2017;6 1620-1630<\/p><p><strong>The multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells)<\/strong><\/p><ol><li>Troyer DL, Weiss ML. Wharton\u2019s jelly-derived cells are a primitive stroma cell population. Stem Cells. 2008 ;26(3):591-9.<\/li><li>John E. Davies, John T. Walker, Armand keating. Concise Review: Wharton\u2019s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cell Translational Medicine 2017;6 1620-1630<\/li><\/ol><p><strong>The MSCs in Wharton\u2019s Jelly\u00a0<\/strong>are<strong>\u00a0the most primitive source with very high regenerative potential<\/strong><\/p><p>Troyer DL, Weiss ML. Wharton\u2019s jelly-derived cells are a primitive stroma cell population. Stem Cells. 2008 ;26(3):591-9.<\/p><p><strong>Mesenchymal Stem Cells are one of the most promising aspects of research and is increasingly being employed in regenerative medicine to treat Spinal cord injury, Cartilage injury, Brain injury, Wound healing, Rheumatoid Arthritis, Multiple sclerosis, Myocardial infraction, Alzheimer, Diabetes, etc<\/strong><\/p><ol><li>Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013 ;34(6):747-54.<\/li><li>https:\/\/clinicaltrials.gov\/<\/li><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers)<\/li><li>Singh Lipi et. al. Stem Cell Overview and Research in Diabetes. Indian Journal of Stem Cell Therapy, 2015:1(1): 29-38<\/li><\/ol><p><strong>Besides MSCs are considered as an immune privileged cell in consequence is being utilized in allogeneic organ transplantation, graft versus host diseases (GVHD) and efficient homing for the hematopoietic stem cell transplantation engraftment<\/strong><\/p><ol><li>Imran Ullah, Raghavendra Baregundi Subbarao, and Gyu Jin Rho. Human mesenchymal stem cells \u2013 current trends and future prospective. Biosci Rep. 2015; 35(2).<\/li><li>Singh Lipi et al. (2016); A Text Book on Laboratory and Clinical Transfusion Medicine. 2016; Volume 3: Good Clinical Transfusion Practices: Chapter 13: Stem Cell Application and Regulations (Nova Science Publishers)<\/li><\/ol><p><strong>Our services include facilitation in the umbilical cord tissue collection, testing, processing and long-term storage of umbilical cord tissue, and its retrieval for any authorized treatment in future, or for participation in clinical trial for research use<\/strong><\/p><p>Imran Ullah, Raghavendra Baregundi Subbarao, and Gyu Jin Rho. Human mesenchymal stem cells \u2013 current trends and future prospective. Biosci Rep. 2015; 35(2).<\/p><p><strong>Disclaimer<\/strong><\/p><ul><li>The umbilical cord tissue banking program is not licensed\/certified by Ministry of Health (MOH) Singapore.<\/li><li>The clinical applications of umbilical cord tissue derived stem cells is under research, and under different phases of clinical trials in Singapore. However, it has not been granted in Singapore as a Standard Clinical Practice.<\/li><li>The clients interested in storing the Umbilical cord tissue of their baby as a precious resource of prenatal tissue, are subject to the clear understanding that stored tissue may never be used for any clinical application until there is enough evidence and approved by local authorities and regulatory guidelines during the time of usage for clinical or research purpose.<\/li><li>Umbilical cord stem cell therapies have enormous promise, but the science in each use is nevertheless in the developmental phase. Professional assessment and expertise is required in using cord tissue derived stem cells for any therapeutic purpose, and we urge anyone embarking on the role of stem cell therapies to confer the National Health Databases to assess current data from clinical trials and the FDA websites on human umbilical cord tissue should also be consulted to obtain its current valuation of any therapy.<\/li><li>This service does not endorse or insure any possible future use or disease cure<\/li><\/ul><p><strong>Breast milk contains the perfect mix of vitamins, protein and fat that are vital to the growth of your infants.<\/strong><\/p><p>https:\/\/www.webmd.com\/parenting\/baby\/nursing-basics#1 Accessed March 13, 2018<\/p><p><strong>It also provides antibodies that help your baby fight off viruses and bacteria, and is known to decrease the risk of them contracting to infections<\/strong><\/p><p>https:\/\/kellymom.com\/pregnancy\/bf-prep\/how_breastmilk_protects_newborns\/\u00a0Accessed March 13, 2018<\/p><p><strong>Mentally, mothers often feel more empowered to see their babies grow and thrive on their breast milk alone<\/strong><\/p><p>https:\/\/www.fitpregnancy.com\/baby\/breastfeeding\/20-breastfeeding-benefits-mom-baby\u00a0Accessed March 13, 2018<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>During pregnancy, if the mother suffers from organ damage, the baby in the womb sends stem cells to repair the damaged organDawe GS, Tan XW, Xiao Z-C. Cell Migration from Baby to Mother.\u00a0Cell Adhesion &amp; Migration. 2007;1(1):19-27.https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2633676\/\u00a0Accessed July 26, 2017 The probability of finding a donor stem cell source through a public bank is low. Banking cord blood with a family bank increases the chances of having a matched unit available. Beatty PG, Boucher KM, [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":8728,"parent":0,"menu_order":255,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/pages\/742"}],"collection":[{"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/comments?post=742"}],"version-history":[{"count":26,"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/pages\/742\/revisions"}],"predecessor-version":[{"id":14913,"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/pages\/742\/revisions\/14913"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/media\/8728"}],"wp:attachment":[{"href":"https:\/\/ontarget-media.com\/cryoviva_new\/wp-json\/wp\/v2\/media?parent=742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}